Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus (itch).

Trevi Therapeutics Announces Positive Results from Phase 2/3 Trial in Uremic Pruritus
Oral Nalbuphine ER trial achieved statistically significant results on the primary endpoint of reducing itch intensity and also demonstrated sustained duration of effect
Trevi Therapeutics Announces Initiation of a Pivotal Study of Nalbuphine ER in Prurigo Nodularis
Study will enroll 60 patients in the United States and Europe